Abstract
Angiogenesis is a key factor in the carcinogenesis process. In oncological practice, angiogenesis inhibition, mainly through the blockade of the VEGF family and its receptors, has been robustly demonstrated to produce clinical benefits and, in specific disease subsets such as colorectal cancer, to extend the overall survival of treated patients. VEGF is a multifunctional growth factor that mediates its functions through cognate receptors on endothelial cells and it has been discovered for its capability to induce macromolecule hyperpermeability in veins and venules.
Several approaches have been taken to target angiogenesis in cancer: drugs that target one or more soluble ligands of the VEGF family, drugs that selectively inhibit one or more receptors of the VEGF receptor family, and drugs that inhibit VEGF receptor(s) among other, non VEGF-related targets. At present, two compounds have shown significant clinical activity, bevacizumab, Avastin® and aflibercept, Zaltrap®, and only one of these (bevacizumab) has so far been registered for use in clinical practice.
In the present review, we explore and summarize the main features of the angiogenetic process, concerning in particular a common and potentially lethal disease as colorectal cancer. We overview the molecular pathways that characterize angiogenesis, focusing on VEGF family, the current applications and limitations of its blockade in oncology, and the hypothetical future perspectives of anti-angiogenic therapy.
Keywords: Angiogenesis inhibitors, Bevacizumab, colorectal cancer, metastasis, neo-angiogenesis, VEGF receptor family
Current Cancer Drug Targets
Title:Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Volume: 12 Issue: 4
Author(s): L. Bagnasco, D. Piras, S. Parodi, I. Bauer, G. Zoppoli, F. Patrone and A. Ballestrero
Affiliation:
Keywords: Angiogenesis inhibitors, Bevacizumab, colorectal cancer, metastasis, neo-angiogenesis, VEGF receptor family
Abstract: Angiogenesis is a key factor in the carcinogenesis process. In oncological practice, angiogenesis inhibition, mainly through the blockade of the VEGF family and its receptors, has been robustly demonstrated to produce clinical benefits and, in specific disease subsets such as colorectal cancer, to extend the overall survival of treated patients. VEGF is a multifunctional growth factor that mediates its functions through cognate receptors on endothelial cells and it has been discovered for its capability to induce macromolecule hyperpermeability in veins and venules.
Several approaches have been taken to target angiogenesis in cancer: drugs that target one or more soluble ligands of the VEGF family, drugs that selectively inhibit one or more receptors of the VEGF receptor family, and drugs that inhibit VEGF receptor(s) among other, non VEGF-related targets. At present, two compounds have shown significant clinical activity, bevacizumab, Avastin® and aflibercept, Zaltrap®, and only one of these (bevacizumab) has so far been registered for use in clinical practice.
In the present review, we explore and summarize the main features of the angiogenetic process, concerning in particular a common and potentially lethal disease as colorectal cancer. We overview the molecular pathways that characterize angiogenesis, focusing on VEGF family, the current applications and limitations of its blockade in oncology, and the hypothetical future perspectives of anti-angiogenic therapy.
Export Options
About this article
Cite this article as:
Bagnasco L., Piras D., Parodi S., Bauer I., Zoppoli G., Patrone F. and Ballestrero A., Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors, Current Cancer Drug Targets 2012; 12 (4) . https://dx.doi.org/10.2174/156800912800190929
DOI https://dx.doi.org/10.2174/156800912800190929 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Elimination of Leukemia Stem Cells; a New Therapeutic Approach in Hemato-Oncology
Current Drug Targets Interaction of Tumor Suppressor p53 with DNA and Proteins
Current Pharmaceutical Biotechnology Chemopreventive Agents Alters Global Gene Expression Pattern: Predicting their Mode of Action and Targets
Current Cancer Drug Targets Intraperitoneal Oncolytic and Tumor Vaccination Therapy with Replication-Competent Recombinant Virus: The Herpes Paradigm
Current Gene Therapy Cyclooxygenase Inhibition and Mechanisms of Colorectal Cancer Prevention
Current Cancer Drug Targets The Therapeutic Impact of Manipulating Microbiota in Inflammatory Bowel Disease
Current Pharmaceutical Design Natural Carriers for siRNA Delivery
Current Pharmaceutical Design TGF-β Pathway as a Therapeutic Target in Bone Metastases
Current Pharmaceutical Design Monoclonal Antibodies in the Management of Solid Tumors
Current Topics in Medicinal Chemistry The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Current Clinical Pharmacology Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope
Current Cancer Therapy Reviews FAK and WNT Signaling: The Meeting of Two Pathways in Cancer and Development
Anti-Cancer Agents in Medicinal Chemistry Strategies to Improve the Killing of Tumors Using Temozolomide: Targeting the DNA Repair Protein MGMT
Current Medicinal Chemistry Rationale and Design of the CAN Study: an RCT of Survival after Propofol- or Sevoflurane-based Anesthesia for Cancer Surgery
Current Pharmaceutical Design Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance
Mini-Reviews in Medicinal Chemistry Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Monoclonal Antibodies Against Epidermal Growth Factor Receptor in Advanced Colorectal Carcinoma: Clinical Efficacy and Markers of Sensitivity&#
Reviews on Recent Clinical Trials B7-H3-targeted Radioimmunotherapy of Human Cancer
Current Medicinal Chemistry